Ignite Creation Date:
2024-05-05 @ 5:19 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00432315
Status:
COMPLETED
Last Update Posted:
2010-09-14
First Post:
2007-02-06
Brief Title:
Docetaxel in Non Small Cell Lung Cancer NSCLC
Sponsor:
Sanofi
Organization:
Sanofi
Study Overview
Official Title:
Multicenter Phase II Study Evaluating Docetaxel and CDDP as Induction Regimen Prior to Surgery or Radiochemotherapy With Docetaxel Followed by Adjuvant Docetaxel Therapy in Chemonaive Patients With NSCLC Stage II IIIa and IIIb
Status:
COMPLETED
Status Verified Date:
2010-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Primary objective
To assess the response rate to induction therapy with docetaxelCDDP
Secondary objectives
To assess
Resectability after induction therapy
Time to progression
Overall survival
Safety profile
Quality of Life
To assess the response rate to induction therapy with docetaxelCDDP
Secondary objectives
To assess
Resectability after induction therapy
Time to progression
Overall survival
Safety profile
Quality of Life
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None